161 related articles for article (PubMed ID: 34343846)
1. Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy.
Wei S; Han Y; Zeng H; Ye S; Cheng J; Chai F; Wei J; Zhang J; Hong N; Bao Y; Zhou J; Ye Y; Meng X; Zhou Y; Deng Y; Qiu M; Tian J; Wang Y
Eur J Radiol; 2021 Sep; 142():109863. PubMed ID: 34343846
[TBL] [Abstract][Full Text] [Related]
2. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
Ravanelli M; Agazzi GM; Tononcelli E; Roca E; Cabassa P; Baiocchi G; Berruti A; Maroldi R; Farina D
Radiol Med; 2019 Sep; 124(9):877-886. PubMed ID: 31172448
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Histopathologic Growth Patterns of Colorectal Liver Metastases with a Noninvasive Imaging Method.
Cheng J; Wei J; Tong T; Sheng W; Zhang Y; Han Y; Gu D; Hong N; Ye Y; Tian J; Wang Y
Ann Surg Oncol; 2019 Dec; 26(13):4587-4598. PubMed ID: 31605342
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Rim on MDCT of Colorectal Liver Metastases: Assessment of Ability to Predict Progression-Free Survival and Response to Bevacizumab-Based Chemotherapy.
Cheng J; Qiu M; Zhang Y; Hong N; Shen D; Zhou J; Wang Y
AJR Am J Roentgenol; 2020 Dec; 215(6):1377-1383. PubMed ID: 32991216
[No Abstract] [Full Text] [Related]
5. Prediction of transformation in the histopathological growth pattern of colorectal liver metastases after chemotherapy using CT-based radiomics.
Wei S; Gou X; Zhang Y; Cui J; Liu X; Hong N; Sheng W; Cheng J; Wang Y
Clin Exp Metastasis; 2024 Apr; 41(2):143-154. PubMed ID: 38416301
[TBL] [Abstract][Full Text] [Related]
6. [Value of histopathological growth pattern in predicting 3-year progression free survival after operation in patients with liver metastasis of colorectal cancer].
Zhang YL; He HJ; Cheng J; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2021 Jan; 50(1):26-31. PubMed ID: 33396983
[No Abstract] [Full Text] [Related]
7. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
Hosokawa A; Yamazaki K; Matsuda C; Ueda S; Kusaba H; Okamura S; Tsuda M; Tamura T; Shinozaki K; Tsushima T; Tsuda T; Shirakawa T; Yamashita H; Morita S; Hironaka S; Muro K
Medicine (Baltimore); 2020 Sep; 99(36):e22060. PubMed ID: 32899071
[TBL] [Abstract][Full Text] [Related]
8. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.
Mazard T; Boonsirikamchai P; Overman MJ; Asran MA; Choi H; Herron D; Eng C; Maru DM; Ychou M; Vauthey JN; Loyer EM; Kopetz S
Gut; 2018 Jun; 67(6):1095-1102. PubMed ID: 29084828
[TBL] [Abstract][Full Text] [Related]
9. Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.
Mazard T; Assenat E; Dupuy M; Mollevi C; René A; Adenis A; Chauffert B; Boucher E; Francois E; Pierga JY; Ducreux M; Ychou M; Gallix B
Dig Liver Dis; 2019 Aug; 51(8):1185-1191. PubMed ID: 31085108
[TBL] [Abstract][Full Text] [Related]
10. Association between primary tumor characteristics and histopathological growth pattern of liver metastases in colorectal cancer.
Bohlok A; Tonneau C; Vankerckhove S; Craciun L; Lucidi V; Bouazza F; Hendlisz A; Van Laethem JL; Larsimont D; Vermeulen P; Donckier V; Demetter P
Clin Exp Metastasis; 2023 Oct; 40(5):431-440. PubMed ID: 37453024
[TBL] [Abstract][Full Text] [Related]
11. Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab.
Li S; Yuan L; Yue M; Xu Y; Liu S; Wang F; Liu X; Wang F; Deng J; Sun Q; Liu X; Xue C; Lu T; Zhang W; Zhou J
Cancer Imaging; 2023 Mar; 23(1):30. PubMed ID: 36964617
[TBL] [Abstract][Full Text] [Related]
12. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
Cremolini C; Milione M; Marmorino F; Morano F; Zucchelli G; Mennitto A; Prisciandaro M; Lonardi S; Pellegrinelli A; Rossini D; Bergamo F; Aprile G; Urbani L; Morelli L; Schirripa M; Cardellino GG; Fassan M; Fontanini G; de Braud F; Mazzaferro V; Falcone A; Pietrantonio F
Br J Cancer; 2018 Apr; 118(7):955-965. PubMed ID: 29531324
[TBL] [Abstract][Full Text] [Related]
13. Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases.
Stremitzer S; Vermeulen P; Graver S; Kockx M; Dirix L; Yang D; Zhang W; Stift J; Wrba F; Gruenberger T; Lenz HJ; Scherer SJ
Br J Cancer; 2020 May; 122(10):1518-1524. PubMed ID: 32205863
[TBL] [Abstract][Full Text] [Related]
14. Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab.
Eefsen RL; Engelholm L; Willemoe GL; Van den Eynden GG; Laerum OD; Christensen IJ; Rolff HC; Høyer-Hansen G; Osterlind K; Vainer B; Illemann M
Int J Cancer; 2016 Apr; 138(7):1777-84. PubMed ID: 26510166
[TBL] [Abstract][Full Text] [Related]
15. Deep learning-based radiomics predicts response to chemotherapy in colorectal liver metastases.
Wei J; Cheng J; Gu D; Chai F; Hong N; Wang Y; Tian J
Med Phys; 2021 Jan; 48(1):513-522. PubMed ID: 33119899
[TBL] [Abstract][Full Text] [Related]
16. Identifying response in colorectal liver metastases treated with bevacizumab: development of RECIST by combining contrast-enhanced and diffusion-weighted MRI.
Liu LH; Zhou GF; Lv H; Wang ZC; Rao SX; Zeng MS
Eur Radiol; 2021 Aug; 31(8):5640-5649. PubMed ID: 33449175
[TBL] [Abstract][Full Text] [Related]
17. Association of CT-Based Delta Radiomics Biomarker With Progression-Free Survival in Patients With Colorectal Liver Metastases Undergo Chemotherapy.
Ye S; Han Y; Pan X; Niu K; Liao Y; Meng X
Front Oncol; 2022; 12():843991. PubMed ID: 35692757
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A
Eur J Cancer; 2017 Mar; 73():74-84. PubMed ID: 27986363
[TBL] [Abstract][Full Text] [Related]
19. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Dohan A; Gallix B; Guiu B; Le Malicot K; Reinhold C; Soyer P; Bennouna J; Ghiringhelli F; Barbier E; Boige V; Taieb J; Bouché O; François E; Phelip JM; Borel C; Faroux R; Seitz JF; Jacquot S; Ben Abdelghani M; Khemissa-Akouz F; Genet D; Jouve JL; Rinaldi Y; Desseigne F; Texereau P; Suc E; Lepage C; Aparicio T; Hoeffel C;
Gut; 2020 Mar; 69(3):531-539. PubMed ID: 31101691
[TBL] [Abstract][Full Text] [Related]
20. Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
Betge J; Barat A; Murphy V; Hielscher T; Van Grieken NC; Belle S; Zhan T; Härtel N; Kripp M; Bacon O; Cordes M; Kay EW; Verheul HM; Neerincx M; Hennessy B; Hofheinz RD; Gaiser T; Ylstra B; Prehn JH; Lambrechts D; Byrne AT; Ebert MP; Schulte N
Digestion; 2016; 94(3):129-137. PubMed ID: 27756074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
